Revance Therapeutics Inc. (RVNC)
Delisted
6 Feb 2025
NASDAQ (NMS) NASDAQ (NMS) Primary $
3. 65
0
0%
$
393.94M Market Cap
- P/E Ratio
- Div Yield
0 Volume
-2.3 Eps
$ 3.65
Previous Close Investors:
Day Range
0 0
Year Range
0 7.56
Want to track RVNC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.80 per share a year ago.
Zacks | 1 year ago
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Revance Therapeutics (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks | 2 years ago
